Evidence map›Paper›PMID 21537410›Full record

ArticleDiabetes & metabolism journal2011

Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study.

Kun Ho Yoon, Jeong Ah Shin, Hyuk Sang Kwon, Seung Hwan Lee, Kyung Wan Min, Yu Bae Ahn, Soon Jib Yoo, Kyu Jeung Ahn, Sung Woo Park, Kwan Woo Lee and 10 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes & metabolism journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01589445. Cited by 24 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01589445 phase4completed

Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.

Ran2008Enrolled77Registered outcomes6Posted comparisons11ConditionsType 2 Diabetes MellitusArmsMetformin hydrochloride, pioglitazone hydrochloride
PMID 8013758PMID 16552630PMID 15677777PMID 20520962PMID 14984448PMID 20695906PMID 15579760PMID 19309251PMID 7623902PMID 17145742PMID 15386821PMID 11118008other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Guideline
  4. Guideline
  5. Guideline
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Article
  11. Observational
  12. Article
  13. Monotherapy in patients with type 2 diabetes mellitus.The Korean journal of internal medicine · 2017
    Review
  14. Review
  15. Monotherapy in Patients with Type 2 Diabetes Mellitus.Diabetes & metabolism journal · 2017
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kun Ho YoonDepartment of Endocrinology, The Catholic University of Korea School of Medicine, Seoul, Korea.
Jeong Ah Shin
Hyuk Sang Kwon
Seung Hwan Lee
Kyung Wan Min
Yu Bae Ahn
Soon Jib Yoo
Kyu Jeung Ahn
Sung Woo Park
Kwan Woo Lee
Yeon Ah Sung
Tae Sun Park
Min Seon Kim
Yong Ki Kim
Moon Suk Nam
Hye Soon Kim
Ie Byung Park
Jong Suk Park
Jeong Taek Woo
Ho Young Son

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated.

methodsWe evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naïve type 2 diabetes mellitus patients in a 48-week, double-blind, randomized controlled study that included 349 Korean patients. Our primary goal was to determine the change in HbA1c levels from baseline to end point. Our secondary goal was to evaluate changes in fasting plasma glucose (FPG) levels, body weight, frequency of adverse events, and the proportion of participants achieving target HbA1c levels.

resultsHbA1c levels decreased from 7.8% to 6.9% in the glimepiride group (P<0.001), from 7.9% to 7.0% in the metformin group (P<0.001), and from 7.8% to 7.0% (P<0.001) in the rosiglitazone group. Glimepiride and rosiglitazone significantly increased body weight and metformin reduced body weight during the study period. Symptomatic hypoglycemia was more frequent in the glimepiride group and diarrhea was more frequent in the metformin group.

conclusionThe efficacy of glimepiride, metformin, and rosiglitazone as antidiabetic monotherapies in drug-naïve Korean type 2 diabetic patients was similar in the three groups, with no statistical difference. This study is the first randomized controlled trial to evaluate the efficacy of commonly-used oral hypoglycemic agents in Korean type 2 diabetic patients. An additional subgroup analysis is recommended to obtain more detailed information.

Indexed as

Diabetes mellitus, type 2GlimepirideMetforminRosiglitazone

Identifiers

PMID21537410
PMCPMC3080564

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.